Current | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

Applied Biosystems Group and Celera Genomics Group Second Quarter FY 2002 Financial Results Scheduled For Release January 23, 2002
Conference Call Scheduled for January 24, 2002

Norwalk, CT - January 15, 2002

Applera Corporation announced today that it will issue fiscal year 2002 second quarter results for Applied Biosystems Group (NYSE: ABI) and Celera Genomics Group (NYSE: CRA) on Wednesday, January 23, 2002. Results are scheduled for release after the close of trading on the New York Stock Exchange.

Tony L. White, Applera Corporation’s chief executive officer, will lead a conference call to discuss these results and to address management’s current financial outlook for the company. He will be joined by Dennis L. Winger, Applera’s chief financial officer, and senior managers from Applied Biosystems and Celera Genomics, who will answer questions from securities analysts and investment professionals. The call is scheduled for 10:00 a.m. (EST) on January 24. Investors, securities analysts, and representatives of the media who would like to participate should dial 800-598-1707 (code “applera”) between 9:45 and 10:00 a.m. International participants should dial (+1) 706-634-4992. This conference call will also be webcast. Interested parties who wish to listen to the webcast should visit either and go to the Investor Relations section of the web site, or and go to the Investor section, or and go to the Investor Relations webpage within the “About Us” section.

About Applera Corporation
Applera Corporation comprises two operating groups. The Applied Biosystems Group develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to market scientific discoveries, leading to the development of new pharmaceuticals, and to conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.6 billion during fiscal 2001. The Celera Genomics Group, headquartered in Rockville, MD, is engaged principally in integrating advanced technologies to create therapeutic discovery and development capabilities for internal use and for its customers and collaborators. Celera’s businesses are its online information business and its therapeutics discovery business. The online information business is a leading provider of information based on the human genome and other biological and medical information. Through the therapeutic discovery business, Celera intends to leverage its genomic and proteomic capabilities to identify drug targets and diagnostic marker candidates, and to discover novel therapeutic candidates. Celera Diagnostics has been established as a joint venture between Applied Biosystems and Celera Genomics. This new venture is focused on discovery, development and commercialization of novel diagnostic tests. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at, or by telephoning 800.762.6923.

Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.